Intermittent Claudication Clinical Trial
Official title:
The Estimation of Ambulation Capacity by History Questionnaire (EACH-Q): An Assessment of Its Validity and Inter-day Reproducibility in Patients With Vascular-type Claudication
Leg artery disease is a common condition in which fatty deposits develop in the blood
vessels that supply the legs. Many patients with leg artery disease experience a cramp-like
leg pain during walking that is relieved by rest; this is called intermittent claudication.
To help determine the severity of leg artery disease, patients may be questioned about how
far they can walk before claudication pain forces them to stop. However, this information is
usually of limited use because most patients poorly estimate their walking capacity. The
investigators have developed a simple questionnaire to help estimate walking capacity in
patients with leg artery disease. The purpose of this study is to test the validity and
reliability of this questionnaire. By validity, the investigators mean the extent to which
the questionnaire measures what it is supposed to measure (walking capacity). By
reliability, the investigators mean the extent to which the questionnaire produces the same
results over time when completed on two different days.
The investigators hypothesise that the investigators simple questionnaire will be valid and
reliable.
Claudication is a chronic condition that impairs walking capacity. Lower-extremity
peripheral arterial disease (PAD) is a frequent cause of claudication. Claudication is
suspected to be vascular-type (i.e. of arterial origin) when pain or discomfort occurs in
the leg muscles during exercise and is relieved within 10 min of rest. The "maximal walking
distance" (MWD; the distance at which pain forces the patient to stop walking) is of great
importance for assessing the severity of claudication. Patient interview is the most readily
accessible way of estimating walking capacity in routine clinical practice; however,
patients with PAD typically poorly estimate their walking capacity. Open questions about the
distance a patient can walk before limb pain or discomfort forces them to stop lack
standardisation. Questions such as "Because of a health or physical problem, do you have any
difficulty walking for one mile?" only allow for a yes/no response. The functional status
component of the 86-item PAVK-86 questionnaire appears useful for estimating MWD, but this
is a time-consuming tool. The Walking Impairment Questionnaire (WIQ), which was proposed
over a decade ago to standardise the estimation of walking capacity by patient interview, is
widely used. However, the WIQ is also relatively complex (14 items with 5 possible answers
for each item: 70 boxes), which often results in a large number of errors when
self-completed by the patient. Furthermore, the WIQ score is difficult to obtain by mental
calculation.
The investigators have developed a simple, 4-item questionnaire, called the Estimation of
Ambulation Capacity by History Questionnaire (EACH-Q), for estimating walking capacity in
patients with symptomatic PAD (vascular-type claudication). The EACH-Q estimates the maximal
duration that can be achieved (8 possibilities ranging impossible to 3 hours or more) at 4
different displacement speeds (from slow walking to running). Scores can be obtained easily
by multiplying the rank of each possible answer (impossible being zero) by a speed factor.
We recently validated the EACH-Q against constant-load treadmill-walking-test performance in
patients suffering from vascular-type claudication. However, further research is needed to
assess the validity of the EACH-Q against other objective tests of walking capacity (e.g.
incremental treadmill-walking test, 6-min walk test), and to assess its reproducibility.
Hence, the aims of this study are: (i) to assess the validity of the EACH-Q against
objective measures of walking capacity obtained from the Gardner-Skinner incremental
treadmill-walking test and the 6-min walk test, and; (ii) to assess the inter-day
reproducibility of the EACH-Q. The results will be compared against those obtained from the
WIQ, and the participant cohort will be patients suffering from vascular-type claudication.
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400395 -
Clinical Trial for GNX80 in Intermittent Claudication
|
Phase 4 | |
Active, not recruiting |
NCT02341716 -
Hospital- and Home-based Supervised Exercise Versus UNsupervised Walk Advice For Patients With InTermittent Claudication
|
N/A | |
Completed |
NCT02041169 -
Lower Extremity Peripheral Arterial Disease and Exercise Ischemia
|
N/A | |
Completed |
NCT00822172 -
Evaluation of Cilostazol in Combination With L-Carnitine
|
Phase 4 | |
Recruiting |
NCT00538408 -
Whole Body Magnetic Resonance Angiography in Ischemic Patients
|
N/A | |
Completed |
NCT00618670 -
Home-based vs. Supervised Exercise for People With Claudication
|
N/A | |
Completed |
NCT00388128 -
Caffeine and Intermittent Claudication
|
Phase 3 | |
Recruiting |
NCT00146666 -
Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)
|
Phase 2 | |
Completed |
NCT00134277 -
Trial Comparing Different Medical Devices for Infragenual Dilatation
|
N/A | |
Completed |
NCT01256775 -
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
|
Phase 2 | |
Completed |
NCT00029991 -
Extract of Ginkgo Biloba (EGB 761) and Vascular Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06299956 -
Supervised Exercise-based Rehabilitation for People With Intermittent Claudication in Denmark
|
N/A | |
Not yet recruiting |
NCT05335161 -
A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
|
Phase 1 | |
Completed |
NCT04390282 -
Secondary Prevention and Application-based Lifestyle Support for Patients With Intermittent Claudication
|
N/A | |
Completed |
NCT03271710 -
Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System
|
N/A | |
Completed |
NCT02380794 -
Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule
|
Phase 2 | |
Active, not recruiting |
NCT02276937 -
Randomized Phase IIb Trial of DVC1-0101
|
Phase 2 | |
Completed |
NCT02097082 -
Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System
|
N/A | |
Recruiting |
NCT00539266 -
Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia
|
Phase 2/Phase 3 | |
Completed |
NCT00071266 -
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
|
Phase 3 |